Clinical Application: Weight Management Techniques You Need

Find out how clinical application of weight management can transform your journey toward a healthier lifestyle and weight control.

Abstract

As a Doctor of Chiropractic and a Board-Certified Family Nurse Practitioner with advanced certifications in functional medicine, I take a comprehensive, integrative approach to patient health. In this educational post, I will explore the complex nature of obesity, viewing it not as a simple matter of willpower but as a chronic, progressive, and relapsing disease. Drawing on the latest research from leading experts, we will delve into the neuroendocrine, metabolic, and genetic factors that regulate appetite and body weight. This discussion will cover the significant role of pharmacotherapy in modern obesity management, comparing different drug classes—from established agents like phentermine to groundbreaking GLP-1 receptor agonists such as semaglutide and tirzepatide—their mechanisms of action, and how to tailor treatment plans to individual patient needs through detailed case studies. We will also address the pervasive issues of weight bias and systemic barriers that hinder effective care. Furthermore, I will explain how our unique multidisciplinary practice in El Paso, Texas, integrates chiropractic care, functional medicine, and medical oversight to provide a holistic and evidence-based journey toward sustainable health and wellness. This synergistic model, which includes the invaluable medical oversight of our Medical Director, Dr. Maria Guadalupe Cardenas, MD, provides a comprehensive framework for achieving sustainable weight loss and improving overall health, addressing not just the symptoms but the root causes of metabolic dysfunction.

Our Integrative Approach at Injury Medical Clinic PA

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, we pride ourselves on a truly collaborative and multidisciplinary model of care. I, Dr. Alex Jimenez, bring a unique dual perspective as a Doctor of Chiropractic (DC) and a Board-Certified Family Nurse Practitioner (APRN, FNP-BC), with extensive training in functional and anti-aging medicine. This allows me to bridge the gap between structural alignment, neurological function, and systemic health. The landscape of obesity management is undergoing a dramatic transformation, and it’s a privilege to share some of the latest findings that are shaping our clinical approach.

Integral to our practice is our Medical Director and Collaborative Physician, Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected, Board-Certified Internist with over 40 years of clinical experience (Texas MD License #J2933, NPI #1164426749). Her deep understanding of internal medicine provides essential medical oversight, allowing us to safely and effectively integrate advanced treatments, including pharmacotherapy for conditions like obesity.

This MD/DC collaboration is the cornerstone of our clinic. Together, our team bridges the gap between different disciplines—combining the structural and neurological benefits of chiropractic care with the diagnostic and prescriptive authority of internal medicine, the root-cause analysis of functional medicine, and the targeted support of rehabilitation and personal injury care. Together, we offer a spectrum of services that includes:

• Integrative Chiropractic Care: Focusing on spinal health, nervous system function, and biomechanics.
• Medical Oversight: Cardenas provides the necessary medical direction for diagnosis, treatment protocols, and prescription management.
• Functional Medicine: We investigate the root causes of chronic disease by examining genetics, lifestyle, and environment.
• Personal Injury and Rehabilitation: Specialized care for patients recovering from accidents, integrating physical therapies with medical and chiropractic treatments.
• Nutritional and Lifestyle Counseling: Empowering patients with the knowledge to make sustainable changes.

This model ensures our patients receive a comprehensive, 360-degree evaluation and a treatment plan that addresses their health from every possible angle, from musculoskeletal integrity to metabolic function. Today, I want to guide you through the evolving world of obesity pharmacotherapy and explain how it fits within our integrative framework to create a powerful, patient-centered journey toward lasting wellness.

Understanding Obesity as a Complex Chronic Disease

For years, I’ve worked with patients suffering from chronic conditions, and my passion has always been to help those struggling with obesity and its related complications. It’s crucial to begin by framing obesity correctly. It is not a failure of character; it is a chronic, progressive, relapsing, and treatable disease. This perspective, officially adopted by organizations like the American Medical Association (AMA) (2013), is fundamental. When my patients stop their anti-obesity medications, their weight often returns. This isn’t surprising—it’s the same principle we see when someone stops their blood pressure medication or cholesterol-lowering agents. The underlying condition resurfaces because it is chronic.

Obesity is profoundly multifactorial, involving a complex interplay of:

• Neurobehavioral Components: Habits, emotional eating, and psychological factors.
• Neuroendocrine Components: The intricate hormonal signaling that governs hunger, satiety, and energy storage.
• Metabolic Components: How the body processes and stores energy.

An increase in body fat promotes adipose tissue dysfunction, where the fat tissue itself becomes a source of inflammation and metabolic disruption. This abnormal fat mass leads to severe health consequences, including debilitating conditions like osteoarthritis from excess joint load and metabolic diseases like type 2 diabetes.

The Scale of the Problem

The statistics are sobering. In the United States, approximately 41.9% of the adult population is classified as having obesity (a Body Mass Index, or BMI, of 30 or higher), and a staggering 9.2% have severe obesity (BMI of 40 or higher). These numbers, detailed in reviews such as Blüher (2019), highlight a public health crisis that requires a sophisticated and compassionate response.

Social and Environmental Factors: The “Determinants of Obesity”

When we discuss health, we often refer to the social determinants of health. I believe it’s more precise to talk about the social determinants of obesity. Disparities are stark when we examine factors like economic stability and access to resources. Centuries ago, poverty was associated with being underweight. Today, the opposite is often true. Energy-dense, nutrient-poor foods are inexpensive and readily available, while access to fresh, high-quality food can be limited in impoverished areas.

Other key factors include:

• Education and Healthcare Access: Lack of quality education and healthcare services creates significant barriers to managing weight.
• Neighborhood and Built Environment: Living in an unsafe neighborhood discourages physical activity, such as walking or jogging.
• Social and Community Context: Cultural perceptions and community norms around body weight can influence individual behaviors and health outcomes.
• Genetic and Hormonal Influences: We are increasingly understanding the roles of hormones such as ghrelin (the “hunger hormone”), GLP-1 (a satiety hormone), and leptin (which regulates energy balance). Research into the gut microbiota is also revealing a powerful connection between our gut flora and weight regulation.
• Technology and Sedentary Lifestyles: Our modern environment, characterized by reduced physical activity and increased screen time, is a major contributor to the global rise in obesity.

The Complex Biology of Appetite Regulation

The complexity of appetite regulation is truly astonishing. Our bodies have a sophisticated neuroendocrine system designed to maintain energy balance. Hormones like leptin, cortisol, ghrelin, and GLP-1 are constantly sending signals among the gut, adipose tissue, and the brain to regulate hunger and fullness. When this intricate system is dysregulated—due to genetics, environment, or other factors—it becomes incredibly difficult for an individual to “overpower” these potent biological signals through willpower alone.

This is a key area where my functional medicine training comes into play. We look for these underlying imbalances and work to restore normal physiological signaling, which complements the structural work of chiropractic care.

Understanding Binge Eating Disorder: A Common Comorbidity

Before we dive into treatments, it’s crucial to understand a condition that often accompanies obesity: binge eating disorder (BED). This is not simply overeating; it’s a recognized clinical diagnosis with specific criteria. My experience in bariatric settings confirmed how prevalent this condition is among individuals struggling with significant weight issues.

BED is characterized by:

• Recurrent Episodes of Binge Eating: This involves eating, in a discrete period (e.g., within two hours), an amount of food that is definitively larger than what most people would eat in a similar period under similar circumstances.
• A Sense of Lack of Control: During the episode, individuals feel they cannot stop eating or control what they eat or how much they eat.
• Associated Behaviors: These episodes are associated with three or more of the following:

• • Eating much more rapidly than normal.
  • Eating until feeling uncomfortably full.
  • Eating large amounts of food when not physically hungry.
  • Eating alone due to embarrassment over the quantity of food consumed.
  • Feeling disgusted with oneself, depressed, or very guilty afterward.

To meet the diagnostic criteria, these binge eating episodes must occur, on average, at least once a week for three months and cause marked distress. Patients often describe getting up in the middle of the night to eat in secret, only to wake up the next morning filled with shame and guilt. Unlike bulimia nervosa, BED is not associated with regular compensatory behaviors like vomiting or laxative abuse. Recognizing and addressing BED is a critical first step, as it has significant implications for mental health and treatment success.

A Crisis of Care: Clinical Inertia and the Pervasiveness of Weight Bias

Despite our growing understanding, a massive gap in care persists. This is what we call clinical inertia. Of the over 100 million people with obesity in the U.S., less than 1% receive a prescription for an anti-obesity medication. Compare this to how we aggressively treat diabetes or hypertension, and the disparity is shocking.

Why do so few health providers diagnose and actively treat obesity? The primary driver is weight bias and stigma. There is a deep-seated, often unconscious, belief that obesity is a result of a lack of willpower. This bias is damaging and has real-world consequences. Research by Puhl & Heuer (2009) shows that patients with obesity experience significant discrimination, which increases their complications and mortality, independent of their weight or BMI. The stress of stigma and the lack of appropriate care are, in themselves, harmful.

Weight bias is truly the last socially acceptable form of discrimination. It is the only bias that has been increasing in the Harvard Implicit Association Test studies. This bias prevents us from providing the care our patients deserve and hampers national efforts to address the obesity epidemic. As healthcare providers, we must first recognize and combat this bias within ourselves.

Starting a New Conversation: How to Approach Weight with Patients

The first step is to change how we talk about weight. We need to move from judgment to partnership. I use several frameworks to guide these crucial conversations:

The 5 A’s Model:

• Ask: “Is it okay if we talk about your weight and its potential effects on your health?”
• Assess: Discuss past weight history, family history, previous attempts at weight loss, diet, and exercise habits.
• Advise: Provide clear, non-judgmental advice about the health benefits of even modest weight loss.
• Agree: Collaboratively set realistic goals. “What would be a goal weight that feels achievable for you?”
• Assist/Arrange: Offer concrete help. “Can I refer you to a nutritionist? Can we talk about medications that might help? Let’s schedule a follow-up to check in.”

The OBESITY Mnemonic:

• Obtain motivation: Build a therapeutic alliance.
• Be aware of stigma: Ensure your office is a safe, judgment-free zone.
• Educate: Explain the chronic nature of obesity.
• Screen: Use history and lab work to identify contributing factors.
• Investigate: Look for other health issues or medications that may be affecting weight.
• Treat comorbidities: Address related health problems.
• Year-long adherence: Work with the patient for long-term success.

Modern Treatment Guidelines for Obesity

Our treatment strategy is tiered based on BMI and the presence of comorbidities (like diabetes, hypertension, or sleep apnea). It’s important to remember that these medications are always an adjunct to—not a replacement for—diet, physical activity, and behavioral modifications.

1. Lifestyle Interventions (BMI ≥ 25 with comorbidities, or ≥ 30): Healthy eating, physical activity, and behavioral therapy are the foundation for everyone. Even a 3-5% weight loss can produce significant improvements in blood sugar, blood pressure, and cholesterol.
2. Pharmacotherapy (BMI ≥ 27 with comorbidities, or ≥ 30): Medications should be considered as an adjunct to lifestyle changes.
3. Bariatric Surgery (BMI ≥ 35 with comorbidities, or ≥ 40): For patients with severe obesity, surgery is a highly effective option that should be discussed.

The goal for the first six months is typically a 5-10% reduction in total body weight. This is a realistic target that delivers substantial health benefits.

A Deep Dive into Pharmacotherapy for Obesity Management

Pharmacotherapy is an essential tool for patients with a Body Mass Index (BMI) over 30, or a BMI over 27 with at least one obesity-related comorbidity (like hypertension or type 2 diabetes). As outlined in guidelines from organizations such as the Endocrine Society (Apovian et al., 2015), medications play a key adjunctive role.

First, Do No Harm: The Role of Obesogenic Medications

Before adding a new medication, my first step is to review a patient’s current medication list. It’s a sad irony that patients with obesity are more likely to be prescribed obesogenic medications—drugs that cause weight gain. This can happen through appetite dysregulation or other physiological mechanisms.

Classes of medications to watch closely include:

• Antidepressants and Antipsychotics
• Mood Stabilizers and Anticonvulsants
• Certain Antidiabetic Agents (e.g., sulfonylureas, insulin)
• Hormonal Contraceptives
• Corticosteroids

If a patient is on a weight-gaining medication, I will collaborate with their prescribing specialist to see if a weight-neutral or weight-loss-promoting alternative is available. For example, a patient with diabetes on a sulfonylurea might benefit from switching to a GLP-1 receptor agonist or an SGLT2 inhibitor.

Short-Term Medications

These drugs are primarily sympathomimetic agents that suppress appetite.

• Phentermine: This is the most commonly prescribed short-term anti-obesity medication. It is an older, relatively inexpensive sympathomimetic amine that acts as an appetite suppressant. While it can be effective, it has a significant side effect profile, including potential for headaches, dry mouth, tachycardia (rapid heart rate), and increased blood pressure. Close monitoring is essential. It is generally approved for up to 12 weeks of use, though some providers may continue it long-term with careful monitoring. A key challenge is tachyphylaxis, in which the body develops tolerance and the medication becomes less effective over time.

Long-Term Medications

These newer agents are designed for chronic management and have transformed our ability to treat obesity.

• Orlistat (Xenical, Alli): A lipase inhibitor that blocks the absorption of dietary fat, available over-the-counter. The fat is instead excreted in the stool. This mechanism also serves as a behavioral disincentive—eating a high-fat meal while on Orlistat can lead to unpleasant gastrointestinal side effects.
• Phentermine/Topiramate (Qsymia): This combination drug pairs the appetite-suppressant effects of phentermine with topiramate, an anticonvulsant that also reduces appetite and may lower leptin levels. It requires a slow dose titration.
• Naltrexone/Bupropion (Contrave): A fascinating combination that targets the brain’s reward system and appetite regulation pathways. Bupropion, an antidepressant, stimulates the POMC pathway in the brain to reduce appetite and increase energy expenditure. Naltrexone, an opioid antagonist, blocks opioid receptors, which helps override a negative feedback loop that would normally dampen the effect of bupropion. Together, they work synergistically to promote weight loss and can be particularly useful for patients with co-occurring depression.
• Liraglutide (Saxenda): A GLP-1 receptor agonist administered as a daily injection. It mimics the natural hormone GLP-1, promoting satiety (fullness), slowing gastric emptying, and reducing appetite. The SCALE trial (Pi-Sunyer et al., 2015) demonstrated its efficacy. The dose is slowly titrated up to 3.0 mg to minimize nausea.
• Semaglutide (Wegovy): A more potent, once-weekly GLP-1 receptor agonist injection. As shown in the landmark STEP 1 trial (Wilding et al., 2021), there was very significant weight loss. Like liraglutide, it requires a gradual dose escalation to a target of 2.4 mg.
• Tirzepatide (Zepbound): This is a groundbreaking dual-agonist medication that acts on both the GIP and GLP-1 receptors. This dual action, as explored in the SURMOUNT-1 trial (Jastreboff et al., 2022), leads to even greater improvements in weight loss and glycemic control than GLP-1 agonists alone. It is also a once-weekly injection with a titration schedule. These agents have demonstrated profound, substantive weight loss that significantly impacts morbidity and mortality. The main drawback is their high cost, although insurance coverage is improving.
• Lisdexamfetamine (Vyvanse): While not approved for obesity, this medication is the only one FDA-approved for moderate to severe binge eating disorder (BED). Since BED is common in patients with obesity, Vyvanse can be a valuable tool for addressing the underlying eating behavior, which in turn can lead to weight loss. It works by impacting neurotransmitters involved in impulse control and focus.

---

Discovering the Benefits of Chiropractic Care- Video

---

Clinical Case Studies: Individualizing Treatment

The “first, do no harm” principle is paramount. Let’s walk through a few clinical scenarios to see how we apply these principles under the collaborative care of Dr. Cardenas and myself.

Case 1: The Patient with Type 2 Diabetes and Hypertension

A 45-year-old male presents with a history of hypertension, type 2 diabetes, and hyperlipidemia. Despite his best efforts with diet and exercise, he has been unable to lose significant weight. He is currently taking glyburide for diabetes.

Our Approach:

1. Describe the Obesogenic Medication: Glyburide is a sulfonylurea that increases insulin production and can increase appetite and weight, working against his goals. We would collaborate to stop this medication.
2. Optimize Current Therapy: We need to assess his metformin dose. It’s common to see patients on a suboptimal dose. The ideal therapeutic dose for diabetes and weight maintenance is typically 1,000 mg twice a day. We would aim to titrate his dose up, monitoring for gastrointestinal side effects.
3. Introduce a GLP-1 Agonist: This patient is an ideal candidate for a medication such as semaglutide (Ozempic). Since he has a diagnosis of type 2 diabetes, his insurance is likely to cover it. This single medication will help control his blood sugar, promote significant weight loss, and potentially improve his blood pressure and lipid profile.

Case 2: The Patient with Prediabetes and Depression

A 38-year-old male with a BMI of 34 has hypertension, prediabetes, and depression. The excess weight is negatively impacting his mental health.

Our Approach:

1. Thorough Diagnostic Workup: We must confirm his glycemic status. I would order not only an A1C but also a fasting blood glucose. A formal diabetes diagnosis would open the door for insurance coverage of a GLP-1 agonist.
2. Consider Naltrexone-Bupropion (Contrave): an excellent option. The bupropion component is an effective antidepressant, addressing his mental health, while the combination has a synergistic effect on weight loss. Improving his mood may lead to increased physical activity and better adherence to lifestyle changes, which will help reverse his prediabetes.

Case 3: The Patient with Binge Eating Disorder

A 32-year-old female with a BMI of 31 presents with anxiety, mild hypertension, and a formal diagnosis of binge eating disorder (BED). Her bingeing episodes are a primary driver of her weight gain and mental distress.

Our Approach:

• Target the Core Disorder: The only FDA-approved medication for moderate to severe BED is lisdexamfetamine (Vyvanse). While it is a stimulant, its ability to reduce the frequency of bingeing episodes is well-documented. For some individuals, improving focus and reducing the chaotic impulses of BED can actually decrease them. We would start with a low dose (e.g., 30 mg daily) and titrate up carefully while closely monitoring her anxiety levels, heart rate, and blood pressure.

The Role of Integrative Chiropractic Care in the Weight Loss Journey

So, how does chiropractic care fit into this modern, pharmacology-inclusive model? The connection is more profound than many realize. It’s the foundation.

1. Improving Biomechanics and Reducing Pain: Excess weight places tremendous stress on the musculoskeletal system. This often leads to chronic pain, which becomes a major barrier to physical activity. Chiropractic adjustments restore proper joint alignment and mobility, reducing pain and making it easier and more comfortable for patients to exercise. By breaking the pain-inactivity cycle, we empower patients to engage with the lifestyle component of their treatment plan.
2. Enhancing Nervous System Function: The spine houses the central highway of the nervous system, which orchestrates metabolism and hormone regulation. Misalignments, or subluxations, can interfere with nerve signals between the brain and the endocrine organs. By correcting these, chiropractic care helps optimize nervous system function, creating a better physiological environment for metabolic health and supporting the very neuroendocrine pathways that medications like GLP-1 agonists target.
3. Stress Reduction and Autonomic Balance: Chronic stress is a major contributor to weight gain through the hormone cortisol. Cortisol promotes fat storage and increases cravings. Chiropractic adjustments have been shown to help shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This balancing of the autonomic nervous system can help lower cortisol levels and mitigate the physiological drive to overeat.
4. Holistic Counseling and Support: As a chiropractor and nurse practitioner, I am uniquely positioned to serve as a health coach. During a chiropractic session, we discuss nutrition, stress management, sleep hygiene, and exercise. This consistent, supportive relationship helps reinforce positive behaviors and keeps patients motivated.

At our clinic, a patient’s journey might begin with a comprehensive evaluation by both Dr. Cardenas and me. We might initiate a GLP-1 receptor agonist to manage appetite while starting a course of chiropractic care to address back pain. This synergistic approach is the essence of true integrative medicine.

Looking Ahead: The Future of Obesity Treatment

The pipeline for obesity medications is incredibly exciting.

• Retatrutide: This investigational drug, a GIP, GLP-1, and glucagon receptor agonist, shows a staggering 24% average weight loss in early data.
• Oral Formulations: The development of oral GLP-1 agonists, such as oral semaglutide and orforglipron, will offer a convenient alternative to injections.
• Novel Mechanisms: Medications like bimagrumab, which targets activin receptors to reduce fat mass while increasing lean muscle mass, represent a new paradigm.

Final Thoughts: A Call for a Comprehensive, Patient-Centered Approach

Managing obesity requires us to be diligent, compassionate, and open-minded. We must move beyond the outdated “eat less, move more” mantra and embrace a scientifically backed, multi-pronged strategy.

My key takeaways for you are:

1. First, Do No Harm: Always start by evaluating for any obesogenic culprits.
2. Individualize Treatment: Tailor medication to the patient’s unique comorbidities.
3. Monitor and Adjust: Obesity is a chronic disease that requires frequent follow-ups.
4. Engage the Patient: Shared decision-making is crucial for adherence.
5. Integrate Care: Combining advanced pharmacotherapy with chiropractic care, functional medicine, and lifestyle coaching provides the most robust framework to help our patients not just lose weight but also reclaim their health and vitality for the long term.

References

(Note: The following references are provided in APA-7 style to support the concepts discussed in the article. Hyperlinks are for informational purposes.)

• American Medical Association (AMA). (2013). AMA adopts new policies on second day of voting at Annual Meeting.
• Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015). Pharmacological management of obesity: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(2), 342–362.
• Blüher, M. (2019). Obesity: Global epidemiology and pathogenesis. Nature Reviews Endocrinology, 15(5), 288–298.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
• Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22.
• Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: A review and update. Obesity, 17(5), 941–964.
• [The Endocrine Society. (n.d.). Obesity ‘Playbook’ for Congressional Staff. Retrieved June 22, 2026, from https://www.endocrine.org/advocacy/obesity-advocacy-initiatives/obesity-playbook-for-congressional-staff](https://www.endocrine.org/advocacy/obesity-advocacy-initiatives/obesity-playbook-for-congressional-staff)
• Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002.

SEO Tags: Obesity Treatment, Weight Loss Medication, Dr. Alex Jimenez, Chiropractic Care, Integrative Medicine, Functional Medicine, El Paso TX, Semaglutide, Tirzepatide, Zepbound, Wegovy, Phentermine, Weight Bias, Chronic Disease Management, Dr. Maria Cardenas, MD DC Collaboration, Appetite Regulation, GLP-1 Agonists, Personal Injury Clinic, Holistic Health, Biomechanics, Nervous System Function, Binge Eating Disorder, Metabolic Health, Pharmacotherapy, Weight Loss Journey, Prediabetes, Type 2 Diabetes